6AM City, LLC (“6AM”) is an audience development company in the local media space, and has developed a disruptive publishing technology platform to curate, package and deliver hyper-local content designed to maximize audience participation, where the public are publishers.
The company engages local communities by creating new ways to consume, experience and share local content. 6AM starts the day by delivering the need-to-know local news conversations, events, and hot topics via a daily email, and then continues the conversation online and across social media channels throughout the day. 6AM is redefining how communities engage, communicate, connect, and experience the cities we serve.
6AM has built a regional platform for advertisers and readers to connect locally. This network of local digital media properties is supported by centralized operations in Greenville, S.C.
Achelios is a Durham-based formulation and clinical stage company with proprietary drug delivery technology that has been demonstrated to provide superior efficacy, reduce adverse effects and increase patient’s convenience and compliance for several diseases including migraine, temporomandibular joint pain as well as, joint muscle pain.
Achelios’ platform allows us to pursue a rapid and low-cost pathway to approval with a higher than average PTRS ensuring maximum return on investment.
Advanced Chemotherapy Technologies
Advanced Chemotherapy Technologies (ACT) has developed a novel device for infusing chemotherapies directly into poorly vascularized tumors such as those found in pancreatic cancer. ACT’s surgically implanted local drug delivery system uses iontophoresis to deliver higher doses of chemotherapies directly into the tumor tissue while lowering systemic toxicity. ACT’s technology has been used to delivery a wide range of drugs, including chemotherapies, immunostimulants and non-viral gene vectors. ACT has completed preclinical testing showing unprecedented tumor regression in pancreatic PDX model, and will be the initiation of a First-in-Human clinical trial in early 2020.
Advanced Nanocoatings Incorporated
Advanced Nanocoatings Incorporated is a highly specialized manufacturing firm that will provide advanced technology Ultra High Wear coated switch components to the low voltage electromechanical switch industry, as a direct replacement for their current internal switch components. We have a letter of intent to purchase our components from the Vice President and General Manager of Electroswitch Electronic Products, a major switch manufacturer that produces millions of switches per year for sales into a global market.
AgEye Technologies’ intelligent horticulture platform combines artificial intelligence (AI) with the Internet of Things (IoT) infrastructure to achieve more efficient farming operations. Through self-learning adaptive analytics, our systems create actionable data that can be acted upon autonomously. Our technology produces better tasting, healthier crops that generate more profit, while also giving better visibility into large scale indoor farming operations.
Allstacks is a predictive forecasting and risk management platform that improves software development outcomes. By running machine learning and AI models across the data from the entire software development life cycle, Allstacks identifies at-risk initiatives then provides solutions to get them back on track.
Altis Biosystems, Inc.
Altis Biosystems, Inc. is a biotechnology company, which spun-out from The University of North Carolina at Chapel Hill. Altis’ patent-pending stem cell technology, RepliGut, recreates both the small and large human intestinal epithelium for drug screening and microbiome research for pharmaceutical and biotechnology companies.
There is an intense need for more accurate drug screening methods using in vitro assays, which can more closely mimic in vivo conditions. Current testing methods using Caco-2 (cancer) cells and animals produce inadequate results, which is one of the primary reasons that only 12% of compounds that begin clinical trials move on to receive FDA approval. Our goal is to reduce the time and cost of drug development by providing a platform that more closely replicates the body’s native biology.
Altis’ technology is a high throughput, scalable, and reproducible platform that can produce a monolayer of proliferative stem cells and terminally differentiated cells. Altis provides a variety of services for customers on its platform, including toxicology, permeability, gene/protien expression, custom cell isolation, etc. In addition to providing services utilizing its platform, Altis is able to ship its platform to customers as well.
Altis is developing a series of formats in addition to its current commercially available platform, providing the next generation of in vitro drug screening platforms. This includes a platform which mimics the anaerobic environment of the microbiome, animal models, disease models, and more.
AnelleO is developing better devices to deliver therapies for women’s unmet medical needs. We 3D print geometrically complex intravaginal rings (IVRs) for sustained, controlled, and targeted drug release. This is a platform technology approach to achieve therapeutic delivery for a variety of indications in women’s health.
Aniluxx Biotechnology is a development stage biopharmaceutical company focused on saving and improving the lives of pets. Our mission is to bring to our pets the same kinds of safe and effective medicines that our human family members enjoy. Our core strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for pets, primarily dogs, cats and horses
Aptus Bioreactors is developing a living heart valve replacement that utilizes a patient’s own cells to grow and regenerate for their entire lifetime. This product will dramatically improve the quality of life outcomes for those young adults who currently face future revision operations or lifelong anti-coagulation medication.
Ares Immunotherapy is a cellular immunotherapy company with a platform technology for the treatment of solid tumors. Our intellectual property is based on a unique subset of T-cells that deliver significant improvements in a solid tumor setting. This potent anti-tumor response is driven by an increased cytokine secretion, improved targeted migration, and prolonged in-vivo persistence powered by a resistance to apoptosis. Our lead candidate is a chimeric antigen receptor T-cell targeted against mesothelin. We are preparing for a first in man trial in mesothelioma followed by subsequent trials in other mesothelin containing solid tumors such as lung cancer and pancreatic carcinoma. The technology was discovered by co-founder and Scientific Advisory Board member, Dr. Chrystal Paulos in her lab at the Medical University of South Carolina.
Arrevus is a North Carolina-based biotechnology company that was founded to address the innovation gap for serious orphan diseases. Dr. Kraus, a former FDA Medical Officer, served on the Infectious Disease Society of America’s Antibiotic Resistance Committee and was also an advisor to the NCATS Global Rare Diseases Registry program. He believes more programs are needed to meet the therapeutic needs of patients with rare diseases. Arrevus was established to address this therapeutic innovation gap. The company has a strong pipeline of novel compounds. The lead clinical asset (oral fusidic acid, ARV-1801) has successfully demonstrated efficacy in a Phase III clinical trial and is currently being developed as a treatment for cystic fibrosis (CF) pulmonary exacerbations. In addition, there are 3 pre-IND programs also targeting serious orphan diseases that span cancer, metabolic, and infectious diseases.
Avior Bio Inc
Avior is a clinical-stage, biopharmaceutical company located in Durham, North Carolina. Our primary focus is neurodermatology. Approximately twenty million Americans suffer for mild to severe form of pruritus or commonly called itch, which occurs in many diseases such as atopic dermatitis, chronic kidney disease, liver disease, hyperthyroidism, psoriasis, etc. Patients that suffer from end-stage renal disease (ESRD) or cholestatic liver disease (CLD) have a dire and critical need for therapy in this space. The cyclic scratch-itch reflex manifests a serious morbidity condition resulting in a debilitating condition of worsening quality-of-life, sleep disturbance, depression, severe excoriation, bleeding, and increased mortality risks. While physicians prescribe corticosteroids and antihistamines for the mild form for both the ailments, these drugs are relatively ineffective in moderate to severe form of pruritus.
Focusing in a $1.3 billion market opportunity, Avior is developing a once-daily (qd) non-invasive, oral transmucosal film product (AV104 Buccal Film) to treat this condition. Avior’s lead product – AV104 buccal film is based on Speedit™ transmucosal film technology and designed for fast onset of action, high bioavailability, and to avoid the first-pass metabolism of the liver. The AV104 buccal film comprises amorphous nano- and microparticles clusters at high concentrations on the surface of the film. (PCT Patent Application No. PCT/US19/19150, and US Patent Application 62/633,907; 62/747,506, PCT/US19/19150). The route of administration results in producing significantly lower amounts of metabolites, which help in reducing the excretory burden in patients.
More than 500,000 babies are born around the globe each year with a treatable, congenital disorder. That’s one baby every minute that dies or is disabled due to lack of accessible newborn screening. Even in the US, with the most mature newborn screening program in the world, there are 150+ diseases with FDA-approved pediatric therapies for which we do not yet screen! The experienced Baebies team, after selling Advanced Liquid Logic to Illumina, has licensed back digital microfluidics to provide highly differentiated products to the newborn screening and pediatric testing markets. The first product, SEEKER, for high-throughput labs – is cleared by the FDA and is now available in both the US and abroad. The company’s second product, the FINDER point-of-care platform, just received its CE Mark and is in clinical trials to support FDA clearance. The addressable markets are large and the potential benefits even larger. The company is expanding its $19 million Series B to complement over $25 million in awarded NIH grants. With two proprietary platforms, a growing installed base, and expanding diagnostic test menus the company is poised for rapid growth.
Basking Biosciences, Inc.
Basking Biosciences Inc. (Basking) was founded in 2019 as to commercialize technology developed at Duke and Ohio State Universities. Basking is developing the first rapidly reversible therapy to restore blood flow to the brain during ischemic stroke. Timely restoration of cerebral blood flow (revascularization), is critical to minimizing permanent damage to threatened brain tissue and is the ONLY intervention that has been proven to improve long term functional outcomes. However, use of pharmacological revascularization has been limited to ~5% of the stroke population due to the risk of hemorrhage associated with the use of rTPA (Activase), the only currently approved treatment for clot dissolution.
Basking’s paired therapy combines an active agent targeting a key component of clot stability with a rationally designed reversal agent that can be administered in the event of bleed to immediately neutralize the active compound and restore the blood’s normal clotting ability. A reversible approach addresses one of the main limitations on the use of tPA where 6-7% of patients suffer a hemorrhage with a 50% mortality rate in that group. A reversible therapy will significantly expand the population eligible for early pharmacological revascularization treatment.
Basking is raising an $18M Series A round to advance the program through two key clinical milestones; Phase 2 proof of concept (revascularization) in ischemic stroke patients and demonstration of reversibility in vivo in patients with underlying cardiovascular disease on background anti-platelet therapy.
Betr Health is a pay for performance digital therapeutics company focused on preventing and reversing several chronic diseases including diabetes, hypertension, GI disorders, anxiety disorders, liver disease, and general well-being. Our proprietary weight loss protocol is rooted in gut health and delivered through personal and remote lifestyle coaches, connected devices, community events, curated content, and our app empowering individuals to become their own best health coach.
BioAesthetics is transforming lives through advancements in biomaterials. Its first product is NACgraft – an acellular tissue graft for regeneration of the nipple-areolar complex (NAC) for patients undergoing breast reconstruction following breast cancer and mastectomy. The company was founded in 2015 by the technology’s inventor Nick Pashos, PhD as a spin-out of his doctoral research at Tulane University in New Orleans, LA. BioAesthetics became operational in April 2017 when it was selected to participate in Batch 5 of IndieBio, the world’s leading life science accelerator, in San Francisco, CA. As of December 2018, the company has completed large animal testing with its NACgraft and anticipates registering the product with the FDA as an HCT/P and being first-in-human early 2020.
BioLink Life Sciences, Inc.
BioLink is a specialty pharmaceutical company focused on the development and commercialization of patented treatments to meet the needs of underserved patient populations. BioLink builds on reformulations of “gold standards of care” to provide novel treatments eligible for approval using the 505(b)(2) New Drug Application route.
BMI has developed the CaVESWave perfusion device that allows for efficient ex-vivo perfusion of donated organs. Currently, BMI is focused on using CaVESWave in two indications, 1) to increase the quantity and quality of donated organs available for transplant and 2) to provide an ex-vivo human organ model system for evaluating pharmacological agents prior to human clinical trials. CaVESWave has several unique advantages compared to other perfusion devices: (1) CaVESWave is the only device that provides a perfusion pulse that is capable of mimicking the arterial pulse; (2) CaVESWave also provides a return Venous pulse; (3) CaVESWave can operate across a wide range of temperatures from hypothermic to normothermic; (4)CaVESWave can perfuse either HEME-based solutions or synthetic solutions; (5) CaVESWave can be used to monitor and measure parameters of function that relate to PK/PD and functional efficacy following treatment of organs with pharmacotherapy or Gene Therapy.
Blue Eye Soft Corp
BES is an (SCRA SC Launch company) -advanced data analytics company focused on product engineering to provide our customers with futuristic solutions powered by ‘humanised’ AI harnessing Big Data Analytics and Web/Mobility services. BES strives for simple, elegant tech solutions in response to complex tasks. As a scalable technology partner we enable organizations to improve operational efficiency and unleash new business potential.
Blue Recruit, Inc
Recruiting used to require a hiring manager to write a time consuming job post, then pay hundreds if not thousands to upload it to one of countless online websites, and lastly waste more of your time and money by getting inundated with endless resumes of candidates that had no business applying for your role. Thankfully, BlueRecruit removes this outdated model by allowing you, the hiring manager, to dictate the exact skills, experience, certifications, education, salary range, location, criminal background, and veteran status you desire. BlueRecruit then provides you the candidates that best fit your profile in an easy to use dashboard. All you need to do is request to connect with a candidate(s) and once that individual(s) accepts your request, you will be provided their contact information. Easy, effective, and cost friendly.
Bundle is an anonymous mortgage shopping platform. Today, mortgage shopping is tough on home buyers because it’s time consuming and leads to a ton of annoying cold calls. At Bundle, we put the home buyer back in control. Our online platform allows home buyers to stay anonymous, creating an easy, pressure-free mortgage shopping experience.
CARL democratizes access to quant hedge fund investing through an elegant and easy to use mobile application that provides access to performance driven investment strategies.
Most hedge funds are limited to investors that can afford to invest millions of dollars – eliminating all but a few of the ultra high net worth individuals or institutional investors.
For the first time, CARL is making quantitative hedge funds available to millions who have never before been able to invest in these types of sophisticated investment strategies.
Cell Microsystems, Inc.
Cell Microsystems is an early growth stage company that develops, manufactures, and markets innovative products for single cell biology with a focus on product applications. The CellRaft® AIR System, an automated platform to image, sort, and isolate single cells using proprietary consumables, has been purchased by leading academic, government, and pharma research organizations. The CytoSort Array is uniquely suited to both end-point destructive analysis of single cells for genomics as well as clonal propagation of single cells for CRISPR gene editing, stem cell research, and organoid development.
CERCA is a data aggregator that leverages individual interest data provided by our members to curate intelligent member-to-member networking connections and enrich customer understanding by association and event hosts. The CERCA mobile application elevates networking (people-finding) to an efficient, lasting & privacy-conscious experience for members. Community & event hosts achieve higher participant engagement, generate sustained brand impressions and receive actionable audience interest insights. In 2019, CERCA completed development of the mobile application and launched two successful beta tests. Efforts in early 2020 are directed towards business development and further improvements to our data management and connection science, supported by a second round of outside investment and initial client revenue.
Cereius aims to improve the lives and survival of patients facing solid tumor brain metastasis through the use of personalized and highly targeted radiotherapy. Our proprietary radionuclide-conjugation techniques allow for highly specific targeting of therapeutic and diagnostic radiation.
Cytex Therapeutics, Inc.
Cytex is developing patented 3D implants that repair cartilage in arthritic joints, thereby restoring pain free joint function. Cytex implants may halt the progression of arthritis and delay or eliminate the need for joint replacement surgery. Cytex lead product, CTX-101, is engineered to repair cartilage in the hip. Currently, there are 470,000 hip replacements annually in the US at a direct cost of $16 Billion. Cytex was founded based on the pioneering regenerative medicine work of Dr. Farshid Guilak, former professor of biomedical engineering at Duke University. Cytex technology is the subject of issued US patents (through 10/2036) and pending international applications now in National phase.
DataClarity helps people easily access, prepare, consume, and visualize any data from anywhere, and transform it into actionable information by fully integrating self-service data virtualization, data science, and data visualization together in a modern digital experience.
Purpose-built as both end-to-end enterprise BI platform and integration hub with analytics fabric architecture spanning on-premises and multiple cloud environments, DataClarity unifies hundreds of unique data sources, models, visualizations, security, and web content across industry-leading BI and AI/ML tools, platforms, and applications.
DermiSense is developing a flexible, bio-inert microneedle platform to access the biofluids just below the skin’s surface, called interstitial fluid (ISF). The platform does not cause pain, does not interface with the blood, and does not require complex chemistry or processing equipment to manufacture or use. It does allow the transport of water vapor and oxygen, can be printed upon, and can be placed on most areas of the body to access dermal ISF. The porous sub-millimeter microstructured needles wick ISF from within the skin with zero power and can either analyze directly on the user or be saturated with ISF and measured off-body with common laboratory tools.
Diveplane® offers AI-powered business solutions across multiple industries. Based on 30+ patent-assets we own, our groundbreaking next generation AI gives you full understanding and control over your automated business processes.
The output of our Diveplane AI platform is comprehensive, defensible, and clear about how it arrived at a certain decision and exactly what data informed that choice. Through human review, Diveplane AI allows an organization to pinpoint and analyze potentially highly biased data and remove it from all future analysis. This experience is entirely different from the black box systems that currently dominate the market. Diveplane AI removes the black box entirely and replaces it with something better altogether.
One of our core products built upon our Understandable AI is GEMINAI, which creates a verifiable synthetic ‘twin’ datasets from real world datasets. GEMINAI preserves the same statistical properties of the original data while removing its real-world confidential or personal information. As a result, GEMINAI helps companies navigate through National & International privacy laws such as GDPR in the EU or HIPAA in the US.
EasyVote Solutions Inc.
EasyVote improves efficiencies, security and transparency in the elections management process for Cities, Counties and States. EasyVote’s SaaS platform uses the latest cloud and mobile app technology to give elections office the needed real time data to make elections run more efficiently. With our module based software, these elections offices can tailor their needs to our software offerings whether its to mange poll workers, keep track of deployment of voting machines, follow campaign finance filings and disclosures or one of the many more tasks performed annually to run successful elections. Using and updating the latest technology through the SaaS platform, makes EasyVote different from our other competitors that continue to build outdated custom software platforms. We have seen strong growth over the last few years leading EasyVote to become a national player in the elections management industry.
Elevon Spotter finds the software bugs that even the best test teams struggle to find. Spotter uses AI to exercise significantly more of an application’s functionality than is possible with existing testing solutions. This enables organizations of any size to ship higher quality software, faster, regardless of the complexity of their application.
Enzerna Biosciences, INC
Enzerna Biosciences is a biotechnology company focused on the development and commercialization of its patented gene therapy approach, called ASRE, for the treatment of rare genetic diseases. ASREs, or Artificial Sequence-specific RNA Endonucleases, are chimeric proteins consisting of RNA endonuclease (cutting) and RNA binding domains. ASREs can be rationally designed to bind and cut any specific 8-nucleotide RNA target. Our technology is uniquely suited to target genetic diseases, namely nucleotide expansion disorders, that cannot be addressed using state of the art CRISPR/Cas DNA editing technologies. Specifically, our scientific founder has published that ASREs can preferentially destroy pathogenic RNAs, which carry expanded CUG repeats in patients with Myotonic dystrophy, and mitigate molecular consequences of the disease in laboratory studies. Our approach will deliver viral vectors coding for therapeutic ASRE proteins to affected tissues to directly destroy pathogenic RNA molecules that underlie the genetic basis of disease. We are developing a portfolio of ASRE-based therapeutics to treat nucleotide expansion disorders, which include Huntington’s Disease, Amyotrophic lateral sclerosis (ALS), Friedreich’s Ataxia, Myotonic dystrophy, and Spinocerebellar ataxia. Enzerna’s executive team has the deep experience needed for rare disease drug development, including experience with two previous drug approvals for Duchenne muscular dystrophy.
Equity Shift is a software platform for private companies, partnerships, and funds which enables customers to digitally manage their own securities. Equity Shift automates the burdensome process of managing compliance for Customers throughout their private life cycle, including new issuances, incentive compensation plans, and secondary transfers.
Whether a Customer’s shares are at-rest or participating in an active transfer event, Equity Shift provides complete digital control within a simple mobile or web-based interface. When changes happen, Equity Shift automates the end-to-end requirements of dealmaking, including board and shareholder approvals, document signing and payment escrow, and transaction closing with transfer of shares and funds.
EternaTear is the next generation OTC artificial tear bringing lasting relief to the millions of people who suffer from progressive dry eye, a painful and often debilitating condition. We are seasoned healthcare product developers and ophthalmic experts with a proven track record. Our team is responsible for developing artificial tears that generate more than $350M in annual revenue.
Evecxia Therapeutics is a privately funded pharmaceutical company co-founded by two Duke scientists, located in the Research Triangle Park, NC, who’s mission is to develop and commercialize EVX-101 to treat patients suffering from disabling, common and costly neuropsychiatric conditions. Having completed an angel round two years ago, Evecxia Therapeutics is currently seeking investors for its Series A financing of $6.5m.
EVX-101 is a first-in-class proprietary oral slow-release technology of 5-hydroxytryptophan (5-HTP) and low-dose carbidopa. We plan to develop and position
EVX-101 as a first-choice adjunctive augmentation therapy in depressed patients responding inadequately to conventional first-line antidepressants (e.g.
Prozac®). The therapeutic mechanism—enhancing serotonin neurotransmission beyond the effect of first-line antidepressants—enjoys clinical proof-of concept
for efficacy and safety. The development of adjunctive EVX-101 is therefore uniquely de-risked. We aim to be in the clinic in 1Q2020.
Depressed patients being treated with first-line antidepressants (e.g. Prozac, Zoloft, Paxil Lexapro, Effexor, Cymbalta, etc.) often times do not achieve an
adequate response to these therapies. Even after optimizing for dose and switching therapies, patients do not adequately respond, numbering between 3 to
4.5 million patients in the US alone. Atypical antidepressants are frequently used as adjunctive treatments but are associated with numerouse safety
considerations and modest efficacy. Safety issues include weight gain, obesity, metabolic issues including diabetes, and motoric dysregulatiuon including
tardive dyskinesias. EVX-101 will be developed and positioned as a first choice adjunctive option driven primarily by its unsurpassed safety and tolerability as
well as its efficacy.
EydisBio, Inc. is a Duke University spin out based on Dr. Tim Haystead’s drug discovery platform – Fluorescence Linked Enzyme Chemoproteomic Strategy (FLECSRx™). The platform has proven highly effective at identifying selective potent small molecule inhibitors. EydisBio recently in-licensed a TAK1 inhibitor (takinib) discovered by the platform from Duke, and off of the takinib scaffold developed a potentially first-in-class lead compound which is highly potent, selective, and orally bioavailable. The compound is currently being tested in various animal models for treating inflammatory autoimmune diseases (e.g., rheumatoid arthritis, lupus, and IBD) as well as for a novel alternative to NSAIDs and opioids for chronic inflammatory and neuropathic pain. By coupling cutting-edge research and understanding of the mechanisms of disease biology with the FLECSRx™ discovery platform to drive innovation, EydisBio is also developing additional small molecules aimed at biologically-relevant targets to meet a variety of unmet medical needs.
FeedStation is a next-gen SaaS product that automates and optimizes complex eCommerce workflows.
Solutions classes include:
– Marketplace feed creation and optimization
– Operations and fulfillments
– Back-office and accounting
– Platform conversations and migrations
– Vertical and category-specific data transformations
Floodlight Software provides a SaaS platform for NDT Inspection companies to run their businesses, enabling them to deliver more inspections, more safely, with accelerated time from quote to cash. Floodlight streamlines inspection processes, consolidates inspection data into a single source of record, and enables smart integration and processing to create a more automated environment supporting IOT and robotic inspection equipment, and creating a rich data source to advance Machine Learning, AI, and analytics. Floodlight helps inspection companies become better at what they do in a more cost-effective manner, making them more profitable and more competitive.
FlowROI is a start-up 506c Real Estate Tech firm based in Wilmington, NC. FlowROI delivers seamlessly integrated tools realtors need every day, from the first contact to close and everything in between. With tech that transforms, FlowROI was designed by Realtors for Realtors. FlowROI helps realtors save time and sell more.
Click on below links to learn more about Flow and their Founder, Sam Ibrahim.
Overview Vid – http://flowroi.com/intro/
Founders Story Vid – https://www.linkedin.com/in/alistair-canal/detail/recent-activity/shares/
Green Stream Technologies Inc
Green Stream is an environmental Internet of Things (eIoT) firm. We are making it more affordable for government and commercial customers to monitor and report environmental conditions – in real time and in high-resolution detail not previously feasible. Better data is key to better response, better decisions and better predictions.
Current projects monitor flooding, rainfall, storm drains, and wetland/stream restoration sites.
Green Stream advises when the water rises!
Hank AI, Inc.
Hank utilizes collective intelligence to build cognitive automation for healthcare. Currently we provide medical coding-as-a-service to revenue cycle management companies. Human medical coders translate medical records from natural language into CPT/ICD/modifier codes inside the Hank medical coding interface. This interface functions as computer-assisted-coding software to improve the human coder’s speed and accuracy while simultaneously capturing key phrases and explanations from the human coder. This is our patent pending workflow integrated knowledge capture platform which allows Hank to reach human level equivalent medical coding on a rapidly increasing percentage of episodes of care. Domestic human coding cost for anesthesia is typically ~$3/case with 100m anesthetics provided in the US each year. We currently have contracts with 3 large anesthesia entities to provide coding-as-a-service, representing ~1% of the anesthesia coding market (~$1.5m ARR). We have 2 large pipeline customers representing ~$20m ARR waiting for us to meet certain metrics. Funding thus far has been provided via a prepayment for services from one of these entities. Global medical coding is a >20billion TAM with ~$15billion spent in the US on human coders and supporting software.
IMMvention Therapeutix, Inc.
IMMvention Therapeutix is therapeutics company focused on improving the lives of patients with rare and prevalent auto-inflammatory diseases that collectively affect >25 million people in the US. The company was co-founded by one of the internationally recognized leaders in the immunology and inflammasome field, Dr. Jenny Ting at UNC-Chapel Hill. Company is just coming out of stealth mode to raise its first venture funding.
Intake is automating preventive care to extend global health spans and save lives. Our NIH & NSF funded technology makes your toilet smart enough to answer the question “Are you healthier today that you were yesterday?”. As you flush, Intake automatically collects a sample of your urine directly from the toilet bowl. It then tests for potentially thousands of diet and health biomarkers. The health trends Intake generates are combined with digital and human interactions to drive improved health outcomes with measurable results. Initially, our platform will be used as a non-drug alternative to manage hypertension which affects 103M US adults. From there we will early diagnose kidney disease, screen for diabetes, and systematically change diet culturally for generations of prevention.
Keen Decision Systems
Keen Decision Systems is an Inc. 5000 software-as-a-service company whose unified marketing measurement and optimization platform helps marketers make dynamic, data-driven decisions that build winning brands. Keen’s platform lets marketers model marketing-mix scenarios to achieve a financial goal.
Named ClickZ’s 2019 Best Predictive Analytics Platform, Keen customers experience a 25 percent uptick in marketing contribution on average in year one. Among the Durham, N.C.-based company’s well-known consumer brands are Post, Arm & Hammer, Boll & Branch, and Nathan’s Famous, among others.
Keen’s platform is among a next-generation of predictive analytics solutions that are leveraging technology and machine-learning to improve the quality of marketing planning and outcomes by: 1) creating a unified view of the financial impact across the entire marketing mix—digital, traditional media and in-store; 2) using data to model future marketing mix options with an accurate estimate of the expected financial contribution, 3) providing real-time access so that models can be updated with new insights any time for in-flight optimization.
Keen was founded by two marketing experts—a former brand executive and a data scientist who bring both expertise and empathy to Keen’s culture and solutions.
LabVoice is the A.I. voice assistant designed specifically with the laboratory in mind.
It allows scientists to have their hands free to focus on the science, while it listens, accesses and records the needed data.
By connecting to scientific equipment and informatics, it lets our customers voice enable their workflows, improving efficiency and compliancy in the laboratory.
LearnPlatform is the edtech effectiveness system for school districts, states and their partners to save time, save money and improve outcomes for all students. Organizations serving over 3million students use LearnPlatform to organize all their edtech, streamline business processes (like procurement, inventory management, and student data privacy) and rapidly analyze which tools are working best for which students.
LearnPlatform is a research-based, mission-driven “for benefit” corporation based in Raleigh, NC, committed to expanding equitable access for all students to the tools and teaching that works best. The high-growth company has become the go-to data source for foundations, researchers and media on what’s actually happening in the expanding $20billion US education technology market.
The company’s unique technology equips educators to run third-party evaluations of their interventions in minutes, instead of months, which has fueled 100%+ revenue growth for the past 4 years. Besides districts and states, the Bill & Melinda Gates Foundation, the International Society for Technology and Education, and Education Week rely on LearnPlatform’s innovative solutions and insights to drive equitable access and market-changing innovations.
Lindy Biosciences, Inc.
Lindy Biosciences is a development-stage company addressing formulation challenges in the rapidly growing biotherapeutics market. Our core technology, Microglassification™, produces spherical, dense, stable particles of a therapeutic protein, ideal for solid injectable formulations such as high-concentration suspensions or encapsulation for controlled release. Over half of all antibody therapeutics are given intravenously, in part because the high dose required cannot be formulated as a solution in a volume small enough for subcutaneous injection. Lindy Biosciences is developing high-dose suspensions of protein that are suitable for subcutaneous injection, decreasing administration costs, increasing patient comfort and compliance, and enabling new high-dose molecules to reach the market.
The mesur.io Earthstream Platform, developed for growers of all types, combines vast amounts of real-time localized data such as weather, satellite, and in-ground sensors – making that information easily usable on any device. Tracking thousands of variables that have been collected and examined using unique machine learning models we provide meaningful advice for critical cultivation decisions from irrigation to fertilization to pest and disease prevention.
Metabolon, Inc., reveals biological insights otherwise unseen. For nearly two decades, the company has been dedicated to building the best metabolomics competency in the world. Today, Metabolon enables, accelerates and supports drug development through biomarker discovery, understanding mechanism of action, patient stratification, and more, as evidenced by more than 2,000 publications, numerous high-impact case studies and customer testimonials.
MicroElastic Ultrasound Systems
For clinicians treating chronic diseases of the skin or prescribing therapies that modify skin structure, Bullseye™ instantly quantifies skin thickness and elasticity. Unlike surface palpation, Bullseye ultrasonically probes the dermis for precise, robust and repeatable measurements, previously unattainable without biopsy. We believe that Bullseye will empower clinicians to identify and connect more patients with earlier interventions, select the right therapy at the right time for each patient, and optimize long-term treatment plans for lasting skin health.
MycoMed improves the success of therapies used to treat cancer, organ failure, and autoimmune diseases by developing products that detect infections early, before progression of disease. Early detection enables personalized, pre-emptive therapies that decreases the burden of infection and improves survival.
NALA Systems, Inc.
NALA Systems is bringing innovation to water purification. We are developing uniquely chlorine tolerant, low fouling, and highly durable reverse osmosis (RO) membranes that will reduce the cost of desalination using RO. Our team of chemists and engineers are applying our patented and patent pending polymers to the production of membranes that will change the way the world purifies water by drastically reducing the cost of RO and enabling the expansion of RO to developing nations in need of potable water.
Newsco brings to the market unique innovation in digital communications. cPro, our Enterprise Communication Intelligence and Content Management Platform is a cloud-based SaaS offering that provides clients control over their corporate communication. Our solution is a market viable solution and currently at 7 pilot sites.
cPro is a powerful asset to allow companies to differentiate themselves with mobility, speed, and accessibility:
• Dynamic, real-time, engaging, and purposeful messaging,
• Set mood and ambiance,
• Develop corporate culture and employee loyalty and
• Build brand and customer loyalty.
• Enterprise tool to create multi channels for distribution to departments/branches/families of businesses.
• Real time content management system centralizing corporate material; allow corporations to flexibly and easily manage communication from one single unified system, pushing and pulling of content to social media sites seamlessly.
• Easily distribute internal content including corporate branding, identity, responsibility, reputation, communication, investor relations or public relations to targeted audience,
• Combine customized external news stories and music relevant to audience to grab attention,
• Multilevel content permissioning, controls and auditing.
Newsco transforms corporate content into engaging corporate channels faster and clearer than anything else providing information and content in a push based manner. This means that messaging in reception areas, common spaces, work areas and any other corporate space can be tailored to the specific audience and combines dynamic media alongside client-generated content. Clients can finitely describe what will be seen, and when, across all the public space monitors on a monitor by monitor basis.
Nufabrx is a proprietary biomaterial platform that embeds active ingredients into fabrics, and these active ingredients can be programmed to respond to the body for predictable, effective, and long-lasting dermal release. Nufabrx products respond to skin temperature and moisture. Fiber-embedded medicine is absorbed into the body during contact with the skin. Nufabrx products are durable and washable up to 25 times without losing effectiveness. Nufabrx’s advanced technology protects fibers from hydrolysis and oxidation for long-term potency. Predictable, controlled delivery for ideal performance. Even with different dosing levels and being processed through numerous wash cycles, ufabrx consistently provides therapeutic delivery of ingredients to the body for pain relief.
One Donation has leveraged technology to create an innovative way to support nonprofits. The benefits of our technology are numerous; including anonymous donations, matching donations, and ability to give to over 1.5 million nonprofits through payroll deduction.
We have positioned our technology to harness two different market forces to gain attraction and adoption. These two market forces are Corporate Social Responsibility and employee engagement.
Corporate Social Responsibility (CSR) has recently become a major buzz word and has had measured effects on a company’s profitability. Millennials make purchasing decisions and employment decisions based on this score, and many others pay attention to it as well.
According to a recent Gallup poll, 80% of Millennials respondents said they would take a 20% reduction in salary to work for a socially responsible employer. The One Donation platform easily interfaces with existing platforms to provide companies with real time data and done for you donation campaigns.
Employee engagement on the other hand has been shown to affect everything from the applicant pool, to productivity, and even absenteeism. Companies who engage their employees see the positive effective effects and companies who do not, do not. The data is clear. The One Donation platform allows companies to engage employees where they are already at, and that is supporting nonprofits they care about.
Simply put, One Donation connects employee engagement and corporate social responsibility with a payroll deduction donation platform. One Donation integrates into existing HR/Payroll platforms and uses blockchain technology to track the transfer of funds.
OpiAID is a data science company creating solutions for addiction. Our goal is to use technology to improve retention of individuals in their drug treatment programs. Those that remain in treatment have significantly better outcomes, while also providing revenue to clinics that deliver excellent care.
Phase Dock Inc.
Nanocomputers (such as Arduino and Raspberry Pi) are revolutionizing STEM Ed and providing new opportunities for makers, engineers and IOT companies. Phase Dock project development kits allow users to mount, organize, protect and transport these fragile electronics as they develop robotics and computer prototypes and projects. This saves precious time and accelerates IoT and electronics/computer prototyping and product development. Innovation skyrockets, learning accelerates and frustration plummets when people can focus on the electronics, mechanics and coding rather than the initial development platform.
PhosphoGam is developing allogeneic cell therapies for cancer using gamma/delta T-cells. The company has best-in-the-world technology to directly expand (manufacture) highly pure and highly active gamma/delta T-cells.
PhosphoGam is unique in that the company’s technology and therapeutic strategy enables repeat doses and has been demonstrated effective in solid tumor applications, neither of which are possible with CAR-T therapy.
Plakous Therapeutics, Inc.
Plakous Therapeutics is a biotherapeutic game changer. We have developed a regenerative medicine to save the lives of premature babies and create pain free lives for adults with osteoarthritis. With our patent pending platform will seek an indication to prevent Necrotizing Enterocolitis (NEC) a Rare Pediatric Disease that afflicts 11% of the 50,000 babies born annually in the U.S weighing less than 3lbs. NEC carries a 30% mortality rate and consumes $5.0B in overall healthcare costs. The market opportunity exceeds $500M. We are also eligible for a priority review voucher worth $100M. Additionally, we will pursue an Osteoarthritis indication, with the potential to drastically reduce knee replacements and provide long-term pain management for millions in this $300B market.
PrimeNeuro is a Durham, NC-based startup that simplifies the complexity of raising a child with autism and in turn provides improved outcomes for the child and family. PrimeNeuro uses a novel combination of objective biomarkers and daily symptom management via an AI knowledge engine to provide trusted recommendations, meaningful connections, and needed resilience while building care teams around the unique needs of every child with autism.
ProAxion’s innovative solutions in vibration and temperature monitoring bring the benefits of data-driven operations and maintenance to the millions of machines that keep our society running. We strive to help define the Industrial Internet of Things (IIoT), taking the term beyond fashionable jargon to effective implementations that combine world-class sensing technologies and a flexible communications infrastructure with cloud-based analytics, machine learning, and diagnostic tools. We are dedicated to developing practical applications for commercial and industrial business needs that enable asset owners to make informed decisions that extend useful life and enhance maintenance effectiveness. ProAxion’s products are designed for the demanding environments of the industrial world and are made right here in the United States.
QATCH is a life-science instrumentation company focused on de-risking drug discovery and preclinical development for biopharmaceutical products. QATCH’s proprietary nanovisQ technology can measure fluid flow behavior with a small drop of formulation and can determine if a protein molecule can become an injection at very early stages of drug development. QATCH is located at Durham, NC and is currently funded through SBIR grants (NSF, NIST).
Redbud Labs®, headquartered in Research Triangle Park, North Carolina, manufacturers cartridge-ready™ microfluidic components for life science industry. MXR™, the world’s fastest, most adaptable microfluidic mixing chip, and STR™, the first cartridge-ready sample prep solution, address some of the industry’s toughest microscale fluidic challenges. Redbud technologies have broad application across a variety of segments including basic research, drug discovery and development, biomanufacturing, point-of-care molecular diagnostics, sequencing, and applied markets. Industry partners seek Redbud’s proprietary Redbud Post™ technology, component design expertise and deep scientific know-how to advance their own next generation products.
Reflekt Me, Inc.
We believe that representation matters and when people see themselves in fashion, media, and commerce they feel valued, validated, and celebrated. Consequently, we seek to create a world that values and uses individual diversity to created hyper-personalized shopping experiences on and offline. Therefore, we have created the Reflekt Me web tool. The Reflekt Me web tool is an e-commerce website hyper-personalization software designed to show how products will look on your consumers relative to their specific characteristics. For example, on a Kohl’s website, online shoppers can view products on real people (not AR/VR) get reviews and tips relative to their body size, not just label size – thereby increasing personalization and satisfaction.
RelayOne is the easiest way for hospitals and OR staff to coordinate surgeries with their surgical teams and approved medical device vendors. We provide a secure platform for both healthcare providers and vendors to view the surgical schedule in real-time and get automatic updates on case status.
Renovion has developed ARINA-1 for the treatment of orphan respiratory diseases. ARINA-1 is an inhaled therapy with more than 25 patient years of efficacy and safety over more than a decade. By targeting chronic inflammatory lung diseases for which there are no FDA-approved therapies, ARINA-1 has an accelerated regulatory path for underserved patient populations.
Our studies in human cystic fibrosis cell cultures have shown that ARINA-1 not only significantly decreases mucus viscosity, but also restores movement of the mucus to transport it out of the lungs. Thick mucus that stagnates in the lung is associated with chronic inflammatory responses and tenacious bacterial infections. Enhancing mucus clearance by reducing mucus viscosity has led Renovion to target cystic fibrosis (CF) and orphan populations of non CF-bronchiectasis patients for small proof-of-concept studies. We will also continue our work to help lung transplant patients, another orphan indication with no FDA-approved therapies. These small populations with no therapies to directly address mucus are attractive starting points for fast entry into a market with a clear need, as well as a gateway to larger markets such as COPD.
Renovion has raised $2.7M to date and is in the process of closing on a round of $4M to fund the proof-of-concept studies outlined above. The initial patent from UNC has been issued and is exclusively licensed to Renovion. Renovion has filed additional Renovion-owned patents for further global protection.
Revibe Technologies, Inc. creates wearable solutions to assist those who struggle with focus, attention and productivity. Their newest platform, Revibe Connect, was partially funded by the US Dept. of Education and is the company’s second successful product offering. This new device leverages researched-based vibration technology coupled with big data and machine learning to help promote focus and independence in children and adults with ADHD, autism and other focusing challenges. Real-time user and clinical data is collected and shared through a mobile app with various stakeholders, such as teachers, parents, school systems and physicians to help drive improved outcomes and efficiencies through data.
RFPi, Inc. (“RFPI” or the “Company”) is bringing to market a technology that will provide doctors the ability to see what in the past they could not; the distribution of blood flow in tissues and vessels. This technology has the potential to disrupt key surgical, wound management and noninvasive medical imaging markets. The Company received FDA 510k approval in Dec 2018 for an open surgical device (iCertaintyTM).
Beginning in 2008, Dr. Bruce Ferguson, an internationally renowned cardiac surgeon, partnered with Dr. Cheng Chen, an expert in imaging and optical physics, to develop RFPi’s technology at East Carolina University (ECU). RFPi began with seed funding in 2014 and engaged professional management shortly thereafter. Jeff Basham, CEO, is a serial entrepreneur with several successful exits, and Peter Geiger, CFO, is a Wharton School MBA and former divisional CFO for a multinational life sciences firm. RFPi has licensed the technology from ECU and is expanding the intellectual property base through further research and development. The company plans to commercialize the technology starting in 2020 in hospital operating rooms in the United States. Future expansion includes the application of the technology in other areas, such as wound clinics, robotic surgical applications, and other geographies.
RFPi is also seeking industry partners to facilitate and/or accelerate these long-term expansion areas. The company has already secured a partner for Japan. In 2017, RFPi signed an investment and license agreement with Nipro Corporation for the Japanese market and intends to launch there in early 2020.
Snthesis is an early stage software company that automates classification, linking, and harmonization of biotechnology research data. Our platform enables organizations to integrate data across systems and teams to empower collaboration, rapid analysis, and more effective, data driven decisions. We draw on a range of emerging technologies to understand and automatically contextualize data as it is captured and then link it to all other existing data in a comprehensive, flexibly searchable knowledge graph that spans the entire organization.
Sparta Biomedical Inc.
For years, we witnessed and experienced first hand the life-stalling and crippling effects of failing musculoskeletal function- whether by athletics, accidents, work, or inevitable aging. Movement is essential to health and critical to quality of life. Movement should not be compromised. Motivated by this and the numerous complications that may arise with surgery, we set out to substantially advance the treatment paradigm within the orthopedic space. Looking at our larger impact as well, we are further compelled to develop and deliver solutions that substantially reduced the lifetime healthcare cost borne by hospitals, payer institutions, and patients
SportGait is the first and only company to enable physicians to follow the Zurich-Berlin guidelines for evaluation and treatment of concussion. We have combined neuromotor and neurocognitive tests in an easy to use Platform-as-a-Service on a Microsoft Surface Pro that supports their clinical decisions from start to finish – injury through recovery. We call this the Safe-to-Safe continuum of care. For more information, please visit www.sportgait.com.
Squirrel Compliancy Solutions, Inc.
Squirrel Compliancy Solutions, Inc. offers a suite of products for US DoD units that have to follow the Defense Information Security Agency (DISA)-Security Technical Implementation Guidelines (STIGS), risk management framework (RMF). Our applications include a comprehensive auditing tool for network infrastructure devices and an automation tool for remediating out of compliance devices. The auditing process is largely manual today taking 30-60 minutes/device with Squirrel software it takes 5 seconds. Our competitors provide inadequate applications which test 1 or 2 conditions per STIG; we average 6 and go 30 conditions deep where required. Squirrel also provides an automation tool for remediating devices. We have one customer who has renewed and currently demonstrating our product in 6 commands. We intend to port our DoD product to civilian RMFs like NERC-CIP, NIST 800-53/800-171, PCI-DSS and ISO-27000 expanding our potential market across all agencies and sectors.
Squirrel was founded by Gilbert Bollinger a network security expert with 23 years of experience as a civilian employee of DoD and at leading network device manufacturers. Advisors include H.P. Shukla an entrepreneur and former US House Representatives – Armed Services Committee member Hon. George J. Hochbrueckner.
Many intrusions are due to improper security settings on network infrastructure devices which can occur due to multiple reasons and continuously monitoring devices is a physically impossible job subject to human error and remediating out of compliance devices is tedious. Squirrel applications make this ‘impossible job’ possible.
StrongKey is making data breaches irrelevant. By providing four specific practices that ensure data, no matter the format, remains encrypted and protected at the highest possible level, we are redefining the way startups, businesses and government agencies secure their information against the inevitability of a breach.
While other security solutions focus on predicting, containing, or looking after the perimeter, StrongKey is different by identifying the most important data, then protecting it (through tokenization and encryption) to ensure data security, even when your employees are phished, or an attacker is on your network.
We’re trusted by some of the largest companies and critical government agencies around the globe, and we have tailored solutions whether you’re a multinational corporation, small business, or just you—working from your home office.
Swell Systems, Inc
Created in 2017, SWELLEnterprise® grew out of the needs of a Wilmington, NC-based graphic and web design firm called DesignLoud. As the company grew, they found that there was a gap in the market for creative firms, a hole where operational functions were being mismanaged and misused (when used at all).
Tools like NetSuite and Salesforce are complicated and expensive. Tools like Ooodoo, ConnectWise and ZoHo didn’t meet the needs of a client-focused design firm.
Derek Schmidt, founder of DesignLoud, decided to develop a software-as-a-service based system that would allow all his remote workers, his customers and his entire team to have access to every component of their workaday world. He developed Swell to make it easier and less expensive to manage projects, clients, business development and communication with remote team members. The cloud-based system manages everything from invoicing to documents, projects to email marketing, replacing 3 or 4 products with just one.
Tellus Therapeutics, Inc.
Tellus Therapeutics is a mission driven life sciences company founded in 2018 to translate groundbreaking research by Duke neonatologist and stem cell biologist, Eric Benner, MD/PhD, into treatments for babies born with brain injury. One in ten babies is born premature and at significant risk for white matter (myelin) injury and subsequent life-long cognitive and neurological impairments, such as cerebral palsy. Tellus is developing novel small molecules derived from human maternal breast milk demonstrated to induce regeneration of myelin-producing oligodendrocytes, reverse white matter injury in an animal models of perinatal brain injury and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury for whom no treatments are available. The potential of the Tellus platform extends beyond treatment of neonatal brain injury into neonatal respiratory and gastrointestinal disorders as well as treatment of adult conditions, including multiple sclerosis, stroke and traumatic brain injury. Tellus is working with regulatory agencies, patient foundations and industry partners to pioneer development of treatments for newborns to provide a lifetime of benefit.
Ten63 Therapeutics is a therapeutics start-up leveraging our proprietary computational platform to develop better, more durable therapeutics against lethal diseases. Our computational platform’s foundation is work done by the founders over the last 10 years at the Donald Lab at Duke University which resulted in over 50 published papers. At Ten63 Therapeutics we drastically extended our platform, improving both its throughput and accuracy. Our unique computational platform allows us to develop better more durable therapeutics capable of drugging yet undruggable targets in order to cure yet incurable diseases. We are engaged in pursuing our own internal pipeline while also engaging in strategic partnerships. Our internal pipeline centers on KRas G12D and other highly validated targets. These targets are well studied, display a clear medical need but are yet undruggable. This strategy allows work on relatively de-risked biology while overcoming the chemistry challenge through our unique and proprietary computational platform. However, Ten63 Therapeutics does not stop there, we understand that many of the most lethal diseases, like cancer, can mutate to develop drug resistance. That is why we have developed the first platform that can predict and overcome drug resistance. Resulting in increased therapeutic durability of our drugs, making our therapeutics both first and best-in-class.
Threat Sketch, LLC
Threat Sketch, LLC (the “Company”) is a North Carolina limited liability company headquartered in Winston Salem, NC. Founded by Rob Arnold in 2015, the Company is a data and analytics firm with proprietary content and risk tools designed to solve large scale cyber risk management problems. The Company’s cyber risk reduction strategies use its data analytics platform, consisting of proprietary databases and assessment tools, for the production of cybersecurity and data privacy solutions. These solutions have been designed to enhance cyber-risk management systems used by consulting professionals, insurance carriers, MSP/MSSP’s, insurance underwriters, law firms and CPA practices.
The Company’s business model is subscription-based for each of its proprietary content and tools: ts mitigationsTM, ts jurisdictionTM and ts supply chainTM. In addition to these proprietary databases, the Company has developed a prototype risk assessment tool, ts decisionsTM, designed to help business leaders (owners, executives, and board members) quantify and manage cyber risks within their respective organizations. Over the last year, the Company has deployed two large-scale implementations of ts decisionsTM for non-profit organizations and small governments, both under contracts with the Department of Homeland Security.
Trio-Labs has developed a proprietary, digital manufacturing technology called Resin Infused Powder Lithography (RIPL), which, when applied to micro-manufacturing, enables new designs, reduces time to market, saves operating costs, and allows for high volume, high speed production. Novel drug delivery and diagnostic devices can be enabled by producing hollow stainless steel micro-needle arrays with our manufacturing technology. Trio Labs will provide printed stainless steel components to customers as a contract manufacturer. Our team’s unique expertise in medical device design and manufacturing will enable us to serve medical customers throughout the entire product life cycle, from design to launch to scale.
TRPblue is developing topical therapeutics that will impact conditions such as chemotherapy-evoked nerve pain of hands and feet, dermato-fibrotic disorders such as excessive scarring, as well as atopic dermatitis / chronic itch by the simultaneous inhibition of two disease-relevant TRP channels with little systemic exposure to the drug. Additionally, this approach holds promise for the treatment of other diverse and complex inflammatory diseases where current treatments remain inadequate.
URO-1 develops products for office procedures in urology. Its first product, the Repris™ Bladder Injection System, is designed after a protocol shown to reduce complications following onabotulinumtoxinA treatment for overactive bladder (OAB). It has been cleared to market by the US FDA. Results from an ongoing pre-commercialization study indicate an order of magnitude reduction in post procedure complications and improved patient tolerance.
The Repris product features the Re4m™ memory cannula/ needle and the Rely™ self-metering syringe. The former enables the user to reach lateral areas of the bladder wall with minimal to no manipulation of the cystoscope. The latter allows delivery of a precise dose of the drug without looking away from the target to visually confirm such delivery. Three patents related to the Repris product line have issued.
A working prototype as well as proof of concept studies in analog tissue of the company’s second product, a variable length, multi-core prostate biopsy system, has been completed. This addresses the clinical and market need for increased tissue samples (12-14 cores), reduced infection risk, improved procedure efficiency and increased patient comfort. Clinical procedures are scheduled in mid-January 2020. Market introduction for this product and the Repris product line is planned for Q2 2020.
Venti LLC was founded by experienced senior industry and military professionals with extensive backgrounds in advanced sensor technologies.
Venti has designed and built:
1. An IoT integrated remote sensing system that will define emergency response, homeland security, and industrial safety.
2. Cloud networked proprietary small, disposable, configurable, and scalable sensors providing responders with graphic and spatial displays in real time.
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc was founded in September 2017 to commercialize first-in-class small molecule 12-LOX products co-invented by Dr. Maloney while he was employed at the National Center for Advancing Translational Science (NCATS) at the NIH. The company’s lead drug product (VLX-1005) is initially targeting Heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT) with expansion into other indications, including Type 1 Diabetes (T1D). HITT is a deadly disease and there are no treatments that target the source of the disease mechanism. VLX-1005 targets 12-Lipoxygenase which disrupts the underlying pathology of HITT offering the potential of a vastly superior treatment to address the unmet clinical need for better therapeutic options. Current treatments only address the end-stage symptoms of the disease, have not improved mortality rates and carry a significant risk of severe bleeding in the patient. VLX-1005 targets the disease source in the platelet and does not cause increased bleeding or impair normal clotting function which distinguishes it from the competition. In diabetes models, VLX-1005 inhibits stress in insulin producing human beta cells and preserves insulin secretion in mouse and human models of diabetes. According to rare disease regulatory experts, VLX-1005 is very likely to receive orphan drug, fast-track and break through status. Clinicians at the point of care agree there is a huge unmet medical need to develop targeted therapies to combat HIT and disease-modifying treatments for diabetes. VLX-1005 will aim to fulfill this unmet need.
VitalFlo is a digital health company focused on helping doctors keep their asthmatic patients out of the ER. We do this by remotely monitoring patient lung function and the air quality around them for potential asthma attack triggers, and leveraging this dataset to develop predictive health analytics and forecasts.
– Commercially available with a several POCs lined up, with an initial commercial go-live date of December, 2019
– Live in our clinical validation study (with UNC School of Medicine)
– Launching with paid partnerships with two studies at Duke Clinical Research Institute
– Launching with the NIH in most comprehensive asthma study in the country
Voxelight’s mission is to enhance health, beauty and wellness by making ultraviolet visible for everyone everywhere. We produce and market both B2B and B2C products that provide a continuum from the store to the home and beyond. Our UVReveal line (B2B) drives sales and our Sunscreenr line (B2C) empowers everyone to take better care of their skin.
ZynBit helps B2B and Financial Service companies automate customer acquisition with data-driven selling. By connecting web, email, calendar and Salesforce data your sales and marketing teams streamline prospecting workflows, automate meeting scheduling and eliminate Salesforce data entry. Productivity for your sales and marketing teams with actionable insights for lead sources, sales activity, territory management and forecasting for sales management and executives.